Literature DB >> 18431251

Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.

Marie Le Mercier1, Véronique Mathieu, Benjamin Haibe-Kains, Gianluca Bontempi, Tatjana Mijatovic, Christine Decaestecker, Robert Kiss, Florence Lefranc.   

Abstract

Galectin (Gal) 1 is a hypoxia-regulated proangiogenic factor that also directly participates in glioblastoma cell migration. To determine how Gal-1 exerts its proangiogenic effects, we investigated Gal-1 signaling in the human Hs683 glioblastoma cell line. Galectin 1 signals through the endoplasmic reticulum transmembrane kinase/ribonuclease inositol-requiring 1alpha, which regulates the expression of oxygen-regulated protein 150. Oxygen-regulated protein 150 controls vascular endothelial growth factor maturation. Galectin 1 also modulates the expression of 7 other hypoxia-related genes (i.e. CTGF, ATF3, PPP1R15A, HSPA5, TRA1, and CYR61) that are implicated in angiogenesis. Decreasing Gal-1 expression in Hs683 orthotopic xenografts in mouse brains by siRNA administration impaired endoplasmic reticulum stress and enhanced the therapeutic benefits of the proautophagic drug temozolomide. These results suggest that decreasing Gal-1 expression (e.g. through brain delivery of nonviral infusions of anti-Gal-1 siRNA in patients) can represent an additional therapeutic strategy for glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431251     DOI: 10.1097/NEN.0b013e318170f892

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  33 in total

Review 1.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

2.  Extracellular stress stimuli alter galectin expression profiles and adhesion characteristics of HL-60 cells.

Authors:  A V Timoshenko; J Lanteigne; K Kozak
Journal:  Mol Cell Biochem       Date:  2016-01-06       Impact factor: 3.396

3.  Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.

Authors:  Florence Lefranc; Véronique Mathieu; Robert Kiss
Journal:  World J Biol Chem       Date:  2011-09-26

Review 4.  Galectins in tumor angiogenesis.

Authors:  Arjan W Griffioen; Victor L Thijssen
Journal:  Ann Transl Med       Date:  2014-09

Review 5.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 6.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

7.  Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.

Authors:  Véronique Mathieu; Nancy De Nève; Marie Le Mercier; Janique Dewelle; Jean-François Gaussin; Mischael Dehoux; Robert Kiss; Florence Lefranc
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression.

Authors:  Dong Tang; Jun Gao; Sen Wang; Nianyuan Ye; Yang Chong; Yuqin Huang; Jie Wang; Bin Li; Wei Yin; Daorong Wang
Journal:  Tumour Biol       Date:  2015-09-01

9.  Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells.

Authors:  Shannon Fortin; Marie Le Mercier; Isabelle Camby; Sabine Spiegl-Kreinecker; Walter Berger; Florence Lefranc; Robert Kiss
Journal:  Brain Pathol       Date:  2009-10-08       Impact factor: 6.508

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.